Rivaroxaban

Merck's fall could enable competitors' drugs to make an impact in the preventative blood clotting space such as Rivaroxaban which was submitted to the FDA by Johnson & Johnson this month and Apixaban which was developed by Bristol-Myers Squibb and Pfizer.

The Big Culprit In Today's DOW Drop - Yahoo! Finance 2011

Rivaroxaban is one of an emerging class of drugs called factor Xa inhibitors that are under development at more than a half-dozen companies to replace older blood thinners including the popular but difficult-to-use blood thinner warfarin.

J&J-Bayer Drug Prevents Clots, but Raises Bleeding Risk in Study Peter Loftus 2011

Rivaroxaban was just approved earlier this month in the U.S. to prevent strokes in patients with a heart rhythm disorder called atrial fibrillation, a problem affecting more than 3 million Americans.

J&J Drug May Have New Role Ron Winslow 2011

Rivaroxaban, from Johnson & Johnson and Bayer AG is awaiting FDA approval and is already on the market in Europe.

Merck Returns Betrixaban Rights Amid Pipeline Review Jonathan D. Rockoff 2011

Rivaroxaban, a once-a-day pill from Johnson & Johnson and Bayer AG , which is on the market in Europe and awaiting U.S. regulatory approval, proved at least as good as warfarin in reducing strokes, better in reducing bleeding and didn't improve survival.

Study Gives Lift to Drug That Cuts Stroke Risk Ron Winslow 2011

Rivaroxaban was discovered by German drugmaker Bayer Healthcare, which already markets the drug in 110 countries around the world.

J&J wins U.S. approval for new blood thinner 2011

Rivaroxaban has been commercially available in Europe under the brand Xarelto since 2008, for the prevention of certain kinds of clots in the legs and lungs in people undergoing hip or knee replacement surgeries.

J&J-Bayer Drug Prevents Clots, but Raises Bleeding Risk in Study Peter Loftus 2011

• Rivaroxaban, from Johnson & Johnson and Bayer, is awaiting FDA approval to prevent stroke.

Study Gives Lift to Drug That Cuts Stroke Risk Ron Winslow 2011

Rivaroxaban was found to be more efficacious than enoxaparin at keeping blood clots from forming.

Anticlotting Drug Faces Panel Vote 2009

Rivaroxaban is a new type of drug that targets an enzyme known as Factor Xa that's involved in the blood-clotting process.

FDA Panel Backs J&J, Bayer Drug 2009